The need for a blueprint emergency plan to avoid a HPAPI crisis

SMi Group21 - 22 October 2019, Boston, USA.
With a massive growth within the HPAPI market, manufacturers cannot afford to be complacent in terms of staff training, utilization of approved technology and blueprint accident plans. Straying away from the correct procedures can have a massive affect on your business and industry.

At the inaugural HPAPI USA conference, these issues will be discussed and give delegates the opportunity to hear from industry experts who will share their experiences and arm attendees with the safety strategies to implement into their organization.

Ayasha Ovals from Taro Pharmaceuticals will provide a keynote address on Day One of the conference, where she will give insights into emergency procedures for HPAPI disasters and how to manage an accident, including long term cost savings, managing risk, fail-safe procedure and forward planning.

Industrial hygiene and potent compound containment will be discussed by Joseph Grill, former Associate Director from Purdue Pharma, where he will share insights on common pitfalls in industrial hygiene, flexible containment and the potential of hastening R&D.

Sakari Consultants, President & Principle, Patricia Weidemanwill focus on training and managing workers with HPAPI exposure, along with the best available techniques for cleaning and waste management. She will also look at technological innovations for containment and transfer technologies, ensuring staff are sufficiently trained and ensure they understand the equipment they are utilising.

The programme with full speaker line-up is available to download at www.hpapi-usa.com

Plus, two HPAPI USA Post Conference Workshops will take place in Boston on October 23rd:

Workshop A: The roadmap from assessing HPAPI hazards to containment implementation along with CDMO dynamics hosted byDr Janet Gould, Principal Toxicologist, SafeBridge Consultants and Charlyn Reihamn, Principle Occupational Health Consultant,SafeBridge Consultants

Workshop B: How to sell your containment project to management: financial justification for containment solutions hosted by DrDavid Eherts, Vice President Global EHS, Allergan Inc

For those interested, an early bird saving of $300 is available for conference tickets booked before Friday 28th June. Register online at www.hpapi-usa.com

Sponsoredby BSP Pharmaceuticals, LONZA, Minakem, SafeBridge Consultants

For delegate enquiries, please contact Fateja Begum on +44 (0)20 7827 6184 or This email address is being protected from spambots. You need JavaScript enabled to view it.

For sponsorship, exhibition and branding enquiries, please contact Alia Malick on +44 (0)20 7827 6168 or This email address is being protected from spambots. You need JavaScript enabled to view it.

For media enquiries contact Neill Howard on Tel: +44 (0)20 7827 6164 This email address is being protected from spambots. You need JavaScript enabled to view it.

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

Regorafenib to be tested in brain cancer patients …

Bayer announced that the regorafenib arm of the platform trial "GBM AGILE" (Glioblastoma Adaptive Global Innovative Learning Environment) opened for enrollment in the US ...

Sanofi and Google to develop new healthcare Innova…

Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping i...

Bristol-Myers Squibb provides update on pending me…

Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation (NASDAQ: ...

Breztri Aerosphere (PT010) approved in Japan for p…

AstraZeneca announced that Breztri Aerosphere (budesonide/glycopyrronium/ formoterol fumarate), formerly PT010, has been approved in Japan as a triple-combination therapy...

Artificial DNA can control release of active ingre…

A drug with three active ingredients that are released in sequence at specific times: Thanks to the work of a team at the Technical University of Munich (TUM), what was o...

Human-on-a-chip model tests cancer drug efficacy a…

A reconfigurable "body-on-a-chip" model could transform drug development by simultaneously measuring compound efficacy and toxicity, for both target cells and other organ...

Pathogen engineered to self-destruct underlies can…

A team of investigators has developed a cancer vaccine technology using live, attenuated pathogens as vectors. A feature of the vaccine causes these bacteria to self-dest...

Novartis successfully completes acquisition of Xii…

Novartis today announced that it has completed its acquisition of Xiidra® (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to trea...

LEO Pharma completes the acquisition of Bayer’s pr…

LEO Pharma and Bayer announced today the achievement of the relevant closing conditions to allow the transfer of Bayer’s global prescription dermatology business to LEO P...

How gastric stem cells fight bacteria

Stem cells are not only key players in tissue regeneration, they are also capable of taking direct action against bacteria. This is the finding of a study conducted by re...

New study showing drug prolongs life for patients …

Women with ovarian cancer who have undergone four or more rounds of chemotherapy typically haven't had much hope that another treatment option will lengthen their lives i...

Pfizer completes acquisition of Therachon

Pfizer Inc. (NYSE: PFE) announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG. Under the ...